Actionable news
All posts from Actionable news
Actionable news in FCS: Fairchild Semiconductor International, Inc.,

Current Trade Stocks Highlights: Christopher & Banks Corporation (NYSE:CBK), Fairchild Semiconductor Intl (NASDAQ:FCS), Koninklijke Philips NV (ADR) (NYSE:PHG), Horizon Pharma (NASDAQ:HZNP)

During Monday’s Current trade, Shares of Christopher & Banks Corporation (NYSE:CBK), lost -0.70% to $1.42.

Christopher & Banks Corporation (CBK) stated results for the thirteen week period ended May 2, 2015.

Results for the Thirteen Week Period Ended May 2, 2015

  • Net sales totaled $91.6 million, as contrast to $103.4 million for the thirteen weeks ended May 3, 2014. During the quarter, the Company operated an average of 6.0% fewer stores than during the comparable period last year, reflecting its MPW store conversion program.
  • Same-store sales reduced 11.7% in the thirteen weeks ended May 2, 2015, as contrast to the thirteen weeks ended May 3, 2014; this follows a 0.2% same-store sales decrease in last year’s first quarter.
  • Gross margin was 35.2% contrast to 36.7% in the first quarter of fiscal 2014.
  • Operating loss was $2.5 million for the thirteen week period ended May 2, 2015. This compares to operating income of $2.8 million in the first quarter of fiscal 2014.

Christopher & Banks Corporation, through its auxiliaries, operates as a retailer of women’s apparel and accessories in the United States. The company designs, sources, and sells women’s apparel and accessories to customers ranging in age from 45 to 60. Its stores offer women’s apparel comprising of knit tops, woven tops, jackets, sweaters, skirts, denim bottoms, bottoms made of other fabrics, leisure wear, and dresses in missy, petite, and women sizes, in addition to jewelry and accessories.

Shares of Fairchild Semiconductor Intl Inc (NASDAQ:FCS), declined -1.11% to $13.77, during its current trading session.

Fibrocell Science, Inc.,, an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, declared that David Pernock, Chairman and Chief Executive Officer, will present at the Ladenburg Thalmann 2015 Healthcare Conference at 1:00 pm EDT on Tuesday, September 29 in New York City. ‘

Fibrocell Science, Inc., an autologous cell therapy company, focuses on developing treatments for skin and connective tissue diseases with unmet medical needs. The company, through its proprietary autologous fibroblast technology, develops azficel-T, which is in Phase II clinical trials for the treatment of vocal cord scarring and...